Megestrol acetate with chemoradiation for stage III lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests whether a special form of megestrol acetate (a medicine used to help with weight and appetite) can improve outcomes when given alongside standard chemotherapy and radiation for people with stage III non-small cell lung cancer. It is for patients who are not overweight and who are not already using other appetite-boosting medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with stage III non-small cell lung cancer (either adenocarcinoma or squamous cell carcinoma) that cannot be removed with surgery.
- You are scheduled to receive both chemotherapy and radiation at the same time (this is called concurrent chemoradiotherapy).
- Your BMI (a measure of body weight relative to height) is 25 or lower.
- You are not currently taking any medications meant to increase appetite or cause weight gain (such as steroids, appetite stimulants, or certain hormone drugs).
- You do not have serious problems with swallowing, vomiting, or digestion that would interfere with eating.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing whether a medication called megestrol acetate (a type of hormone that can boost appetite and help with weight gain) can improve outcomes for people with advanced non-small cell lung cancer who are malnourished. It is used as part of first-line treatment, meaning before any chemotherapy for the advanced cancer.
This study tests a new form of megestrol, a medicine that helps stimulate appetite and promote weight gain, in people with advanced non-small cell lung cancer who are starting their first chemotherapy and are at risk of malnutrition. The goal is to see if it improves nutrition and overall well-being during treatment.
This study tests a medicine called nanocrystalline megestrol acetate to see if it can help improve appetite and promote weight gain in people with advanced non-small cell lung cancer who are losing weight. If you qualify, you would receive this treatment alongside your regular care to help you feel better and maintain your strength.
This trial tests a drug called megestrol acetate to help people with advanced lung cancer who are losing weight or have poor appetite. It aims to improve nutrition and quality of life.
This study tests whether adding a drug that boosts appetite and weight to standard lung cancer treatment helps people with advanced small cell lung cancer who are experiencing weight loss and poor appetite. It aims to improve quality of life and treatment outcomes.
This trial tests a medicine called megestrol acetate (a type of hormone therapy) given after surgery to see if it helps improve appetite and weight in people with high-risk head and neck cancer. It is given alongside the usual radiation and chemotherapy treatment.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.